Editorial
MALT Lymphomas - A Closer Look in the Genomics Era
Abstract
In 1832, an article titled “On some morbid appearances of the absorbent glands and spleen” was published in the journal ‘Medico-Chirurgical Transactions’.1 The author was Thomas Hodgkin (Fig. 1). Thus began an era of the study of a distinct group of tumors involving the lymphatic system, what we refer to today as the ‘lymphomas.’ Presently, lymphoid neoplasms are usually classified into Hodgkin and non-Hodgkin lymphomas. The current WHO classification describes more than 30 different types of non-Hodgkin lymphomas.2 Among these, the three most common types include the diffuse large B-cell lymphomas (approximately 31%), follicular lymphomas (approximately 22%), and the mucosa-associated lymphoid tissue (MALT) lymphomas (approximately 8%).3,4This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Medico-Chirurgical Transactions 1832;17:68–114.
2. Jaffe ES, Harris NL, Stein H, et al, (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press; 2001.
3. Harris NL, Stein H, Coupland SE, et al. New approaches to lymphoma diagnosis. Hematology Am Soc Hematol Educ Program 2001:194–220.
4. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–3918.
5. Ahlawat S, Kanber Y, Charabaty-Pishvaian A, et al. Primary mucosa-associated lymphoid tissue (MALT) lymphoma occurring in the rectum: a case report and review of the literature South Med J2006;99:1378–1384.
6. Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. N Engl J Med 2004;350:213–215.
7. Voulgarelis M, Moutsopoulos HM. Lymphoproliferation in autoimmunity and Sjogren’s syndrome. Curr Rheumatol Rep 2003;5:317–323.
8. Lenzen R, Borchard F, Lubke H, et al. Colitis ulcerosa complicated by malignant lymphoma: case report and analysis of published works. Gut 1995;36:306–310.
9. Mizushima T, Sugiyama T, Komatsu Y, et al. Clinical relevance of the babA2 genotype of Helicobacter pylori in Japanese clinical isolates. J Clin Microbiol 2001;39:2463–2465.
10. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:6370–6378.
11. Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004;18:1722–1726.
12. Hosaka S, Akamatsu T, Nakamura S, et al. Mucosa-associated lymphoid tissue (MALT) lymphoma of the rectum with chromosomal translocation of the t(11;18)(q21;q21) and an additional aberration of trisomy 3. Am J Gastroenterol 1999;94:1951–1954.
13. Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology2005;128:1579–1605.
14. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999;93:3601–3609.
15. Akagi T, Motegi M, Tamura A, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999;18:5785–5794.
16. Morgan JA, Yin Y, Borowsky AD, et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 1999;59:6205–6213.
17. Zhang Q, Siebert R, Yan M, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999;22:63–68.
18. Banham AH, Beasley N, Campo E, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 2001;61:8820–8829.
19. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175–1186.
20. Lehours P, Menard A, Dupouy S, et al. Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Infect Immun 2004;72:880–888.
21. Rollinson S, Levene AP, Mensah FK, et al. Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood2003;102:1007–1011.
22. Wu MS, Shun CT, Huang SP, et al. Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma.Haematologica 2004;89:1015–1017.
23. Wu MS, Chen LT, Shun CT, et al. Promoter polymorphisms of tumor necrosis factor-alpha are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma. Int J Cancer2004;110:695–700.
24. Reimer P, Fischbach W, Goebeler ME, et al. Decreased frequency of HLA-B35 in patients with gastric MALT lymphoma. Ann Hematol 2004;83:232–236.
25. Zinzani PL, Stefoni V, Musuraca G, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer2004;100:2190–2194.
26. Streubel B, Ye H, Du MQ, et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004;66:476–480.
27. Raderer M, Wohrer S, Bartsch R, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:8442–8446.
28. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741–2745.
29. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol2005;23:1979–1983.
30. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol2005;23:6415–6420.
31. Wadlow R, Ramaswamy S. DNA microarrays in clinical cancer research. Curr Mol Med 2005;5:111–120.
32. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931–945.
33. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531–537.
34. Chin KV, Kong AN. Application of DNA microarrays in pharmacogenomics and toxicogenomics.Pharm Res 2002;19:1773–1778.
35. Chicurel ME, Dalma-Weiszhausz DD. Microarrays in pharmacogenomics–advances and future promise. Pharmacogenomics 2002;3:589–601.
36. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
37. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
38. Sutton P, O’Rourke J, Wilson J, et al. Immunisation against Helicobacter felis infection protects against the development of gastric MALT Lymphoma. Vaccine 2004;22:2541–2546.
39. Mueller A, O’Rourke J, Chu P, et al. Protective immunity against Helicobacter is characterized by a unique transcriptional signature. Proc Natl Acad Sci U S A 2003;100:12289–12294.
40. Press Release: The 2005 Nobel Prize in Physiology or Medicine. Available at:http://nobelprize.org/medicine/laureates/2005/press.html. Accessed December 17, 2005.
41. National Cancer Institute. NCI Challenge Goal 2015 - Eliminating the Suffering and Death Due to Cancer. Available at: http://www.cancer.gov/aboutnci/2015. Accessed December 8, 2005.
